The IgG glycome of SARS-CoV-2 infected individuals reflects disease course and severity

Front Immunol. 2022 Oct 18:13:993354. doi: 10.3389/fimmu.2022.993354. eCollection 2022.

Abstract

Immunoglobulin G (IgG) antibodies play an important role in the immune response against viruses such as SARS-CoV-2. As the effector functions of IgG are modulated by N-glycosylation of the Fc region, the structure and possible function of the IgG N-glycome has been under investigation in relation to divergent COVID-19 disease courses. Through LC-MS analysis we studied both total IgG1 and spike protein-specific IgG1 Fc glycosylation of 129 German and 163 Brazilian COVID-19 patients representing diverse patient populations. We found that hospitalized COVID-19 patients displayed decreased levels of total IgG1 bisection and galactosylation and lowered anti-S IgG1 fucosylation and bisection as compared to mild outpatients. Anti-S IgG1 glycosylation was dynamic over the disease course and both anti-S and total IgG1 glycosylation were correlated to inflammatory markers. Further research is needed to dissect the possible role of altered IgG glycosylation profiles in (dys)regulating the immune response in COVID-19.

Keywords: COVID-19; IgG glycosylation; SARS-CoV-2; anti-spike IgG; total IgG.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • COVID-19*
  • Glycosylation
  • Humans
  • Immunoglobulin G*
  • SARS-CoV-2

Substances

  • Immunoglobulin G
  • Biomarkers